Topline Results: Verrica’s VP-315 Performs Well in BCC Trial
Verrica Pharmaceuticals Inc.’s VP-315 is showing promise in the treatment of basal cell carcinoma, according to Part 2 of its Phase 2 clinical trial. VP-315 is a potential first-in-class oncolytic peptide immunotherapy designed to be administered directly into a tumor to induce immunogenic cell death. All patients treated with VP-315 had a reduction in tumor […]